Dapagliflozin treatments seem to reduce left ventricular mass (LVM) in people with type 2 diabetes (T2D) and left ventricular hypertrophy (LVH), according to the results of the DAPA-LVH study published in the European Heart Journal.

Alexander J.M. Brown, MD, FACC, et al., evaluated the efficacy of dapagliflozin 10 mg once daily treatment over a 12-month period, compared with a placebo in 66 adult patients with T2D, LVH and controlled blood pressure (BP). The mean age of study participants was 67 and 38 were male. The primary endpoint was change in absolute left ventricular mass (LVM), assessed by cardiac magnetic resonance imaging.

Results found dapagliflozin significantly reduced LVM compared with placebo (-3.95 ± 4.85 g vs. -1.13 ± 4.55 g; P = 0.018, with an absolute mean change of -2.82g). In addition to a decrease in LVM, researchers also observed reductions in secondary endpoints including weight, systolic BP, visceral and SCAT, insulin resistance, and high-sensitivity C-reactive protein.

To the authors' knowledge, this is the first randomized controlled trial investigating the effect of dapagliflozin on LVH in patients with T2D. Despite the small study size, Brown and colleagues note "the regression of LVM suggests dapagliflozin can initiate reverse remodeling and changes in left ventricular structure that may partly contribute to the cardio-protective effects of dapagliflozin."

Clinical Topics: Noninvasive Imaging, Magnetic Resonance Imaging

Keywords: Hypertrophy, Left Ventricular, Blood Pressure, Insulin Resistance, Diabetes Mellitus, Type 2, Glucosides, Benzhydryl Compounds, Heart Ventricles, Body Weight, Magnetic Resonance Imaging

< Back to Listings